166 related articles for article (PubMed ID: 30858290)
1. Safety of Intravenous Iron - Cosmofer and Monofer Therapy in Peritoneal Dialysis and Non-Dialysis-Dependent Chronic Kidney Disease Patients.
Sivakumar C; Jubb VM; Lamplugh A; Bhandari S
Perit Dial Int; 2019; 39(2):192-195. PubMed ID: 30858290
[TBL] [Abstract][Full Text] [Related]
2. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
3. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
4. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
5. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
6. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
8. A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status.
Bhandari S; Allgar V; Lamplugh A; Macdougall I; Kalra PA
BMC Nephrol; 2021 Mar; 22(1):115. PubMed ID: 33784968
[TBL] [Abstract][Full Text] [Related]
9. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.
Atalay H; Solak Y; Acar K; Govec N; Turk S
Hemodial Int; 2011 Jul; 15(3):374-8. PubMed ID: 21564503
[TBL] [Abstract][Full Text] [Related]
10. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
[TBL] [Abstract][Full Text] [Related]
11. Correction of iron deficiency anaemia using IV CosmoFer in CKD patients with asthma: a prospective study.
Syed A; Bhandari S
QJM; 2016 Mar; 109(3):187-90. PubMed ID: 26101227
[TBL] [Abstract][Full Text] [Related]
12. Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients.
Solak Y; Atalay H; Guney I; Turkmen K; Kaya E; Turk S
Ren Fail; 2011; 33(3):307-11. PubMed ID: 21401355
[TBL] [Abstract][Full Text] [Related]
13. Review of available intravenous iron preparations in hemodialysis.
Palmer K; Cameron K; Battistella M
CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
[No Abstract] [Full Text] [Related]
14. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
Goldstein SL; Morris D; Warady BA
Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582
[TBL] [Abstract][Full Text] [Related]
15. [Parenteral iron therapy: problems and possible solutions].
Hoigné R; Breymann C; Künzi UP; Brunner F
Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron therapy and risk for progressive loss of kidney function in patients with chronic kidney disease.
Mansour W; Bissram M; Rosner MH
Nephron Clin Pract; 2011; 118(2):c189-94. PubMed ID: 21178375
[TBL] [Abstract][Full Text] [Related]
17. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients.
Prakash S; Walele A; Dimkovic N; Bargman J; Vas S; Oreopoulos D
Perit Dial Int; 2001; 21(3):290-5. PubMed ID: 11475345
[TBL] [Abstract][Full Text] [Related]
18. Clinical update: intravenous iron for anaemia.
Auerbach M; Ballard H; Glaspy J
Lancet; 2007 May; 369(9572):1502-1504. PubMed ID: 17482969
[No Abstract] [Full Text] [Related]
19. Iron status and benefit of the use of parenteral iron therapy in pre-dialysis Chronic Kidney disease patients.
Arogundade FA; Soyinka FO; Sanusi AA; Ojo OE; Akinsola A
Niger Postgrad Med J; 2013 Dec; 20(4):299-304. PubMed ID: 24633272
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
